
Epizyme EPZM
Quarterly report 2022-Q2
added 08-09-2022
Epizyme Interest Expense 2011-2025 | EPZM
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -22.4 M | -4.68 M | -13 K | -25 K | 32 K | 83 K | 79 K | 59 K | -81 K | -78 K | -23 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 83 K | -22.4 M | -2.46 M |
Quarterly Interest Expense Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -5.39 M | -5.48 M | - | -5.64 M | -5.58 M | -5.48 M | -3.97 M | -1.72 M | -885 K | 413 K | 1.15 M | 1.86 M | 2.24 M | -6 K | - | -6 K | -11 K | 18 K | - | -32 K | 10 K | 4 K | - | 21 K | - | - | - | - | - | 20 K | - | 17 K | 12 K | 12 K | - | 3 K | -50 K | -39 K | - | -39 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.24 M | -5.64 M | -1.02 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
4.08 M | $ 25.37 | -2.07 % | $ 1.23 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.75 | 1.61 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
2.95 M | $ 3.28 | -2.53 % | $ 254 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-807 K | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-20.7 M | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
65.5 M | $ 210.49 | 0.16 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.34 | -2.47 % | $ 8.04 B | ||
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
-12.6 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.66 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.35 | 3.07 % | $ 14.8 M | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
1.36 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
ChromaDex Corporation
CDXC
|
3 K | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
286 M | $ 568.3 | -2.19 % | $ 43 B | ||
|
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-257 K | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
444 K | - | -7.23 % | $ 13 M | ||
|
Biogen
BIIB
|
250 M | $ 174.78 | 1.32 % | $ 25.4 B | ||
|
BioVie
BIVI
|
4.3 M | $ 1.46 | -3.31 % | $ 2.16 M | ||
|
Cortexyme
CRTX
|
-102 K | - | -1.05 % | $ 67.1 M | ||
|
Benitec Biopharma
BNTC
|
-126 K | $ 12.34 | -4.78 % | $ 508 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
16.4 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-7.26 M | $ 11.5 | 0.52 % | $ 744 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
-1.65 M | - | -5.68 % | $ 8.28 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 0.28 | -2.28 % | $ 609 M | ||
|
Catalyst Biosciences
CBIO
|
1.04 M | $ 14.62 | -4.54 % | $ 962 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Cerus Corporation
CERS
|
1.98 M | $ 2.17 | 0.7 % | $ 401 M | ||
|
Enochian Biosciences
ENOB
|
122 K | - | - | $ 40.5 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M |